Claims:

1. A compound selected from the group consisting of:

compounds of formula (I)



(I)

wherein

U is O or a lone pair,

V is a) O, S, NR^1, or CH_2, and L is lower-alkylene or lower-alkenylene,

b) -CH=CH- or -C≡C-, and L is lower-alkylene or a single bond,

W is CO, COO, $CONR^2$, CSO, $CSNR^2$, SO_2, or SO_2NR^2,

X is hydrogen or one or more optional halogen and/or lower-alkyl substituents,

m is 2,

n is 0 to 7,

A^1 is hydrogen, lower-alkenyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy, or thio-lower-alkoxy,

A^2 is cycloalkyl, cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkinyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy or thio-lower-alkoxy,

A^3 and A^4 independently from each other are hydrogen or lower-alkyl, or

A^1 and A^2 or A^1 and A^3 are bonded to each other to form a ring and $-A^1-A^2-$ or $-A^1-A^3-$ are lower-alkylene or lower-alkenylene, optionally substituted by R^3, in which one $-CH_2-$ group of $-A^1-A^2-$ or $-A^1-A^3-$ can optionally be replaced by NR^4, S, or O,

A^5 is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkyl optionally substituted with hydroxy or lower-alkoxy, alkenyl optionally substituted with hydroxy, or alkadienyl optionally substituted with hydroxy,

R^3 is hydroxy, lower-alkoxy, thio-lower-alkoxy, $N(R^5,R^6)$, or lower-alkyl optionally substituted by hydroxy,

R^1, R^2 , R^4, R^5, and R^6 independently from each other are hydrogen or lower-alkyl;

pharmaceutically acceptable salts of compounds of formula (I); and

pharmaceutically acceptable esters of compounds of formula (I).

2. The compound according to claim 1, wherein U is a lone pair.

3. The compound according to claim 2, wherein V is O or CH_2, and L is lower-alkylene or lower-alkenylene.

4. The compound according to claim 2, wherein V is -C≡C- and L is lower-alkylene or a single bond.

5. The compound according to claim 3, wherein n is 0.

6. The compound according to claim 3, wherein A^1 is lower-alkyl.

7. The compound according to claim 6, wherein A^1 is methyl or ethyl.

8. The compound according to claim 3, wherein A^2 is lower-alkenyl, or lower-alkyl optionally substituted by hydroxy or lower-alkoxy.

9. The compound according to claim 8, wherein A^2 is 2-propenyl or 2-hydroxy-ethyl.

10. The compound according to claim 3, wherein A^1 and A^2 are bonded to each other to form a ring and -A^1-A^2- is lower-alkylene or lower-alkenylene, optionally substituted by R^3, in which one -CH_2- group of -A^1-A^2- can optionally be replaced by NR^4, S, or O, wherein R^3 and R^4 are as defined in claim 1.

11. The compound according to claim 3, wherein A^3 is hydrogen.

12. The compound according to claim 11, wherein A^4 is hydrogen.

13. The compound according to claim 3, wherein A^5 is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, or lower-alkyl optionally substituted with hydroxy or lower-alkoxy.

14. The compound according to claim 13, wherein A^5 is phenyl or benzyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine and chlorine, or wherein A^5 is lower-alkyl.

15. The compound according to claim 14, wherein A^5 is phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, butyl, or pentyl.

16. The compound according to claim 3, wherein W is COO, $CONR^2$, CSO, or $CSNR^2$, and R^2 is hydrogen.

17. The compound according to claim 3, wherein X is hydrogen.

18. The compound according to claim 3, wherein X is fluorine.

19. A compound selected from the group consisting of:

compounds of formula (VII)



(VII)

wherein

V is O or CH_2;

L is lower-alkylene or lower-alkenylene;

W is COO, CONH, CSNH or CSO;

A^1 is hydrogen or lower-alkyl;

A^2 is lower alkyl or lower alkenyl;

m is 2; and

A^5 is lower alkyl, phenyl or lower alkyl phenyl, wherein the phenyl group is optionally substituted with halogen;

pharmaceutically acceptable salts of compounds of formula (VII); and

pharmaceutically acceptable esters of compound of formula (VII).

20. The compound according to claim 19, wherein V is CH_2.

21. The compound according to claim 19, wherein V is O.

22. The compound according to claim 21, wherein W is COO.

23. The compound according to claim 21, wherein W is CONH.

24. The compound according to claim 23, wherein the compound of formula (VII) is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.

25. The compound according to claim 24, which is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.

26. The compound according to claim 21, wherein W is CSNH.

27. The compound according to claim 21, wherein W is CSO.

28. A process for the manufacture of a compound selected from the group consisting of:

compounds of formula (I)



(I)

wherein

U is O or a lone pair,

V is a) O, S, NR^1, or CH_2, and L is lower-alkylene or lower-alkenylene,

b) -CH=CH- or -C≡C-, and L is lower-alkylene or a single bond,

W is CO, COO, $CONR^2$, CSO, $CSNR^2$, SO_2, or SO_2NR^2,

X is hydrogen or one or more optional halogen and/or lower-alkyl substituents,

m is 1 or 2,

n is 0 to 7,

A^1 is hydrogen, lower-alkenyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy, or thio-lower-alkoxy,

A^2 is cycloalkyl, cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkinyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy or thio-lower-alkoxy,

A^3 and A^4 independently from each other are hydrogen or lower-alkyl, or

A^1 and A^2 or A^1 and A^3 are bonded to each other to form a ring and $-A^1-A^2-$ or $-A^1-A^3-$ are lower-alkylene or lower-alkenylene, optionally substituted by R^3, in which one $-CH_2-$ group of $-A^1-A^2-$ or $-A^1-A^3-$ can optionally be replaced by NR^4, S, or O,

A^5 is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkyl optionally substituted with hydroxy or lower-alkoxy, alkenyl optionally substituted with hydroxy, or alkadienyl optionally substituted with hydroxy,

R^3 is hydroxy, lower-alkoxy, thio-lower-alkoxy, $N(R^5,R^6)$, or lower-alkyl optionally substituted by hydroxy,

R^1, R^2, R^4, R^5, and R^6 independently from each other are hydrogen or lower-alkyl;

which process comprises:

a) reacting a compound of formula (II)



(II)

with a compound $(A^1,A^2,U)N\text{-}C(A^3,A^4)\text{-}L\text{-}M$, wherein V is O, S or NR^1, M is mesylate, tosylate, triflate, Cl, Br or I, and U, A^1, A^2, A^3, A^4, A^5, L, W, X, m, n and R^1 are as defined above, or wherein HV is mesylate, tosylate, triflate, Cl, Br or I, and M is OH, SH or NHR^1, and R^1 is as defined above,

or b) reacting a compound of formula (III)



(III)

with a compound NHA^1,A^2, wherein M is mesylate, tosylate, triflate, Cl, Br or I, and A^1, A^2, A^3, A^4, A^5, L, V, W, X, m and n are as defined above,

or c) reacting a compound of formula (IV)



(IV)

with a compound $(A^1,A^2,U)N\text{-}C(A^3,A^4)\text{-}L\text{-}C{\equiv}CH$, wherein M is Br or F_3CO_2SO, and U, A^1, A^2, A^3, A^4, A^5, L, W, X and m are as defined above,

or d) reacting a compound of formula (V)



(V)

with a compound $(A^1,A^2,U)N\text{-}C(A^3,A^4)\text{-}L\text{-}M$, wherein M is mesylate, tosylate, triflate, Cl, Br or I, and A^1, A^2, A^3, A^4, A^5, W,U, L, X, m and n are as defined above,

or e) hydrogenating a compound of formula (VI)



(VI)

wherein V is -C≡C-, and A^1, A^2, A^3, A^4, A^5, U, W, L, X, m and n are as defined above.

29. A pharmaceutical composition comprising a compound according to claim 1 and at least one of a pharmaceutically acceptable carrier or pharmaceutically acceptable adjuvant.

30. A method for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, which method comprises administering a compound according to claim 1 to a human being or animal.